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The use of stems cells in tendon repair is of particular interest given the frequency of tendon injuries worldwide together with the
technical diﬃculty often encountered when repairing or augmenting tendons. Stems cells have the capability to diﬀerentiate into a
varietyofdiﬀerentcelltypesincludingosteocytesandtenocytes,andifnormalarchitectureofdamagedtendon(eithermacroscopic
ormicroscopic)couldberestored,thiswouldsigniﬁcantlyimprovethemanagementofpatientswiththeseinjuries.Thereisalready
encouraging research on the use of stems cells clinically although considerable further work is required to improve knowledge and
clinical applications of stem cells in tissue engineering.
1. Anatomyand Pathophysiology of
Tendon Damage
Tendons attach muscle to bone and function to transmit
tensile loads from muscle to bone and to enable the muscle
belly to be at an optimal distance from the joint. The mi-
crostructural composition is approximately 20% cellular
(ﬁbroblastssecreting collagen)and 80% extracellular matrix.
The extracellular matrix consists of mainly water, collagen,
a n dg r o u n ds u b s t a n c e[ 1].
More than 90% of collagen in tendons is type 1 with the
remainder being type 3. These molecules are aligned in par-
allel to form microﬁbrils, which are further aggregated to
form bundles [1]. This allows them to handle high unidi-
rectional tensile loads. Ground substance consists mainly of
proteoglycans, glycoproteins, and plasma proteins. These
bindtheextracellularwaterinthetendon,helpingtostabilise
the collagenous skeleton and contributing to the overall
tendonstrength.Elastin,secretedbyﬁbroblasts,formshighly
cross-linked sheets, allowing the tendon to stretch and coil,
contributing to tissue recovery after loading.
The tendinous zone of insertion (enthesis) is a progres-
sive structural change from tendon to bone, resulting in in-
creased stiﬀness and decreased stress concentration. It is
oftenthesiteoftendinopathicchangeandinjury.Itisdivided
into four zones; parallel collagen ﬁbres at the end of tendon,
unmineralised ﬁbrocartilage, and mineralised ﬁbrocartilage,
which merges into cortical bone [1].
The blood supply to tendons is inferior to that of most
other connective tissues. The blood supply is through a
sparsesupplyofarteriolesoravincula(mesotenon)andsub-
sequent diﬀusion through the tendon substance. They have a
low metabolic rate. Both these factors have implications for
the intrinsic healing potential of the tissue [1].
Thereareanumberoffactorsaﬀectingthebiomechanical
properties of tendons and subsequent tendinosis (degenera-
tive tendon) or tendinopathy (an inﬂammatory reaction sec-
ondary to rupture or vascular damage) [2]. Ageing results in
a decrease in collagen diameter and number. Endocrine fac-
tors play a part, and pregnancy is associated with a decreased
stiﬀness of pelvic tendons. Pharmacological agents such as
corticosteroids and anabolic steroids are associated with ten-
donrupture.Systemicdiseaseandgeneticsaﬀecttheintrinsic
healing potential. Repetitive microtrauma and fatigue failure
often leads to calciﬁcation and an inﬂammatory reaction.
Macrotrauma results in the acute rupture of a tendon due to
a force above the ultimate tensile strength, either at the ten-
dinous insertion onto bone or in the tendon substance itself.
The healing response is variable and usually poor. There
is an initial rapid haemorrhagic and inﬂammatory phase.
This is followed by a proliferative phase, with ﬁbroblast pro-
duction of new matrix. Remodelling occurs several weeks2 Stem Cells International
after injury consisting of maturation and orientation of col-
lagen ﬁbres. Although there are external inﬂuences aﬀecting
tendon repair which can be controlled, there are intrinsic
metabolic limitations to healing. Often a surgical solution is
necessary to repair or reconstruct tendon. Rotator cuﬀ tears
and subsequent repair illustrate the magnitude of the prob-
lem. Rotator cuﬀ injuries accounted for 4.4 million outpa-
tient appointments in the US in 2003 [3]. It is estimated that
at least 13% of individuals between the ages of 50 and 59
and 51% of people over the age of 80 experience rotator
cuﬀ injuries [4], and over 50,000 patients in the US require
direct repair each year [5]. Despite this, repair can fail up to
40% of the time, leading to impaired shoulder biomechanics
and subsequent weakness and degenerative osteoarthritic
changes [6]. Tissue engineering and the use of stem cells has
sought to provide a solution to this common cause of mus-
culoskeletal morbidity.
2. Stem-Cell Potential
Stem cells may be totipotent, pluripotent, or multipotent,
depending on tissue type. Totipotent cells form all the cells
and tissues that contribute to the formation of an organism.
Only the embryo itself is totipotent. Pluripotent stem cells
(PSCs) can form most cells of an organism from all three
germcelllayers.Embryonicstemcellspresentinthefertilised
oocyte, zygote, and morula [7]. Pluripotent cells have the
ability to expand in vitro almost indeﬁnitely and form tis-
sues from ectoderm, mesoderm, or endoderm. There are
concerns about tumour formation in vivo and major ethical
concerns, however, which have thus far restricted their use.
Multipotent cells form a number of cells or tissues that
are usually restricted to a particular germ layer. Multipotent
cells are derived from speciﬁc tissue compartments in the
adult. The two main types of multipotent stem cell are
haemopoietic and mesenchymal type, and both are usually
derived from adult bone marrow, but occasionally from fat,
skin, periosteum, and muscle. Mesenchymal stem cells
(MSCs) are multipotent, capable of diﬀerentiating into sev-
eral connective tissue types including osteocytes, chondro-
cytes, adipocytes, tenocytes, and myoblasts [8]. Mesenchy-
mal stem cells have the advantage of being easily obtainable
in adult tissue and, with the appropriate microenvironment
can diﬀerentiate into various target tissue types.
Research on tendon healing and the use of stem cells has
thus far been limited to animal studies, with the majority
using mesenchymal stem cells.
2.1. Mesenchymal Stem Cells. MSCs can arise from a number
of sources as already highlighted. Kryger et al. [9] isolated
tenocytes, sheath ﬁbroblasts, bone-marrow-derived stem
cells,andadiposestemcellsfromadultrabbitsandusedthem
in a ﬂexor tendon model. Although adipose-derived stem
cells proliferated faster in culture, at six weeks, there was
no diﬀerence with regards to cell viability, senescence, or
collagen expression.
Tempfer et al. [10] examined biopsies of intact human
supraspinatus tendons and showed that stem cell tendon
precursors (tenocytes) were present in the tissue. Pryce et al.
[11] showed that TGF beta signalling may play an important
role in the recruitment of tenocytes. Mazzocca et al. [12]
aspirated bone marrow from the bone anchor tunnel in the
humeral head during arthroscopic rotator cuﬀ repair in 23
patients. Using a novel device, in the operating room, stem
cells were isolated from this aspirate and their presence and
osteogenic potential conﬁrmed. This study showed that stem
cell-rich bone marrow is exposed following arthroscopic
drilling of the humeral head. These stem cells harbour po-
tential to diﬀerentiate into osteoblasts and tenocytes to re-
generate the bone-tendon interface. Novel solutions for the
recruitmentandactivationofthesecellsincombinationwith
growth factors, gene therapy and an appropriate scaﬀold
may provide improved strength of the rotator cuﬀ following
surgical repair.
Awad et al. [13] showed that there was a signiﬁcant im-
provement in tendon repair when MSCs were injected into
patellar tendon defects in rabbits. Compared to a cell-free
collagen control at four weeks, MSC-mediated repair tissue
demonstrated signiﬁcant increases in stress, modulus, and
strain energy density of 26%, 18%, and 33%, respectively.
Chong et al. [14] examined the histology and modulus of
Achilles tendon defects in rabbits over a 12-week period.
Comparedtocontrols,itwasshownthatatthreeweeks,there
was an improvement in collagen organisation and modulus
in the MSC group. By 12 weeks, however, this diﬀerence was
insigniﬁcant, suggesting that MSCs may improve tendon
healing in the early stages only.
The tendon-bone interface is a common site of rupture,
especially at repetitive low-loading forces, for example, in
rotatorcuﬀtendinopathy.Changetal.[15]examinedhealing
potential of infraspinatus tendon in rabbits at the tendinous
insertion using a periosteal graft containing autologous
MSCs. Histological examination from 4 to 12 weeks showed
gradual progression in healing from ﬁbrotic tissue to min-
eralised ﬁbrocartilage. There was an associated signiﬁcant
increase in failure load with time compared to controls.
Ju et al. [16] used Achilles tendon grafts in a rat anterior
cruciate ligament model (ACL). He undertook an ACL re-
construction and then injected the tibiofemoral bone tunnel
with MSCs. Tendon-bone analysis at 2 weeks showed the
proportion of collagen ﬁbres at the interface tissue was sig-
niﬁcantly higher in the MSC group compared to controls.
At 4 weeks in both groups, the implanted tendon appeared
to attach directly to bone. The beneﬁt of injecting MSCs,
therefore, may give early beneﬁt in this model. A study by
Nourissat et al. [17] evaluated healing at the tendon-bone
interface at the Achilles tendon in a rat model. After the
tendon-bone interface was destroyed, the tendon was either
left to heal, or an injection was given of chondrocytes or
MSCs. At 45 days, it was found that cell injection of either
chondrocytes or MSCs signiﬁcantly improved healing com-
pared to controls left to heal without an injection. A new
enthesis was produced in the injection groups but not in
controls, and in only the MSC group was this organised as
in normal enthesis tissue.
The treatment of tendonitis by stem cells was studied by
Lacitignolaetal.[18]inhorses.Tendonitiswasinducedbyan
injection of collagenase into the superﬁcial ﬂexor tendons.Stem Cells International 3
Three weeks later, bone marrow mesenchymal cells, bone
marrow mononucleated cells, or controls of ﬁbrin were in-
jected into the tendons. In the stem cell-treated groups, there
was signiﬁcantly improved healing histologically with a
higher collagen type 1 to type 3 ratio and improved ﬁbre
orientation compared to controls. Another equine ﬂexor
tendon model for tendonitis compared MSCs, MSCs with
insulin-like growth factor-1 (IGF-1) gene-enhanced MSCs,
and controls. Both IGF-1 MSCs and MSC groups showed
signiﬁcantlyimprovedtendonhistologyat8weekscompared
to controls [19].
2.2. Pluripotent Stem Cells. Watts et al. [20] reported on the
use of an injection of foetal-derived embryonic-like stem
cells for superﬁcial ﬂexor tendon injuries in horses. Com-
pared to controls at eight weeks, there was no signiﬁcant dif-
ference in tendon matrix gene expression, proteoglycan, col-
lagen,orDNAcontentbetweenthetendons.Therewas,how-
ever, improved tissue architecture, tendon size, lesion size,
and linear ﬁbre pattern in the lesions treated with stem cells.
The tensile strengths of the healing tendons were not tested,
however.
Turner et al. [21] reviewed the use of amniotic stem cells
for the engineering of a diaphragmatic tendon graft in new-
born lambs. Failure rate was higher in the control group
(acellular prosthetic graft). Tensile strength testing and col-
lagen levels were signiﬁcantly higher in the grafts containing
stem cells.
The use of stem cell-coated sutures could have obvious
theoretical beneﬁts in surgical repair of tendons. Yao et al.
[22] evaluated the fats of pluripotential embryonic stem cells
seeded to a suture carrier in acellularised, sectioned rabbit
Achilles tendon. At day 5, ﬂuorescence under microscopy
showed live metabolically active pluripotential cells at the
tendon repair site. The same author showed that cell adher-
ence at seven days was greater in FibreWire sutures when ﬁrst
coated with poly-1-lysine or ﬁbronectin [23].
G u e s te ta l .[ 24] examined the diﬀerence between MSCs
and embryo-derived PSCs injected into damaged superﬁcial
digital ﬂexor tendons in horses. At 90 days following injec-
tion, there had no signs of immune reaction to the allogenic
PSCs and no sign of tumour formation. Survival rate was
greater, with PSCs maintaining a constant level over 90 days
in contrast to MSCs which showed less than 5% survival
over ten days and a subsequent decline thereafter. PSCs also
showed an ability to migrate to other areas of damaged
tendon in contrast to MSCs.
2.3. Tissue Engineering for Tendon Regeneration. There are
now several studies illustrating the potential for the use of
stem cells not only in tendon repair, but also other their use
in other tissue engineering applications [25–29]. Several
studieshaveshownthatamechanicalstimulusimprovesten-
don healing. It has been shown in patellar tendon defects in
rabbitsthattwoweeksofinvitromechanicalstimulationsig-
niﬁcantly increased collagen type 1 and collagen type 3 gene
expression of stem cell-collagen sponge constructs. These
constructs exhibited 2.5 times increased linear stiﬀness and
4 times the linear modulus of controls [30]. The degree of
mechanical loading has been shown to aﬀect cell diﬀer-
entiation. One study showed that low mechanical in vitro
stretching of MSCs into tenocytes, where as larger stretching
at 8% induced diﬀerentiation into adipocytes, chondrocytes,
and osteocytes [31]. In clinical practise, lipid accumulation
and calciﬁcation in a healing tendon may lead to pain and a
detrimental functional outcome.
In vivo, the extracellular matrix of tendon provides ﬁ-
broblasts with the architecture to support development and
function. During tissue engineering, therefore, a scaﬀold is
needed to mimic this matrix. The optimal cell: matrix ratio
to support tendon function is debated. Juncosa-Melvin et
al. [32] examined cell: collagen ratios in Achilles tendon
defects in rabbits. It was shown that constructs with a lower
cell density at 12 weeks achieved higher stiﬀness and mod-
ulus values. Nirmalanandhan et al. [33] showed that above
a threshold value of cell density, percentage reductions in
collagen concentration inﬂuence contraction kinetics more
than equivalent percentage increases in cell seeding density.
The alignment of stem cells on scaﬀolds may be important.
Yin et al. [34] showed that foetal stem cells placed in ran-
domly oriented scaﬀolds in vitro led to osteogenic diﬀer-
entiation. In contrast, aligned nanoﬁbres induced the for-
mation of spindle-shaped cells and tendon-like tissue. Obvi-
ously, controlling scaﬀold conditions is vital to the eﬀective
diﬀerentiation of these cells and the ultimate mechanical
properties of the healing tissue.
Butler et al. [35] found that in rabbits with patellar ten-
don defects, there appeared to be 4 important factors which
improved the biomechanical properties of the healing ten-
don. Replacing the suture with end posts in culture and
lowering the MSC concentration in cell-scaﬀold constructs
resulted in failure forces greater than peak in vivo forces that
were measured for all activities and tangential stiﬀness simi-
lartonormaltendon.Augmentingthescaﬀoldgelwithatype
1collagenspongeincreasedrepairstiﬀness,andmechanically
stimulating these constructs further improved biomechanics
in the healed tendon.
2.3.1. Use of Growth Factors in Tissue Engineering. Recently,
Gulotta et al. [36] has highlighted the importance of gene
expression in stem cells for tendon healing. In a rat suprasp-
inatus model, MSCs after injection were present and meta-
bolically active, but no diﬀerence in the biomechanical
strength of the repairs, the cross-sectional area, peak stress to
failure, or stiﬀness compared to controls could be found. A
further study compared an MSC group and a group who
had received adenoviral MT1 matrix metalloproteinase-
transduced MSCs (Ad-MT1-MMP). Although no diﬀerence
was found at 2 weeks, at 4 weeks, the Ad-MT1-MMP group
had signiﬁcantly more ﬁbrocartilage, higher load to failure,
stress to failure, and stiﬀness values as compared to MSCs
[37]. It has also been shown that MSCs expressing BMP-2
and the transcription factor Smad8ca lead to diﬀerentiation
into a tenocyte lineage [38]. It has been proposed that
expression of Smad8ca lead to the production of MMPs.
Shahab-Osterloh et al. [39] showed that MSCs with adeno-
viral-induced Smad8ca and BMP-2 exhibit both tendinous
and osteogenic properties in mice and can aid formation,4 Stem Cells International
therefore, of bone-tendon interface. Numerous other studies
highlight the beneﬁcial eﬀect of BMP in tendon-bone inter-
face healing [40].
The quality of tendon that forms from bioengineering
may be a concern still, with ectopic bone formation being
a problem in the healing tissue. Harris et al. [41] showed
that this is likely related to alkaline phosphatase activity and
may be higher in 3D in vitro constructs compared to tissue
engineering on a 2D monolayer.
3. Summary
Tendon healing is limited by numerous intrinsic and extrin-
sic factors [42–47]. These have implications for the athlete
in a “macrotrauma” acute rupture setting or in repetitive
microtrauma leading to tendonitis. Like all connective tis-
sues, tendon is vulnerable to the eﬀects of ageing, inevitably
leading to cell senescence of tenocytes, resulting in an extra-
cellular matrix devoid of collagen and weakened tissue. The
principles of tissue engineering involve a complex interplay
of factors [48–52]. Local delivery of growth factors, the use
of plasmids, and scaﬀolds are several. These in combination
with stem cells or genetically modiﬁed stem cells have been
shown to contribute to tendon healing in numerous animal
studies [53–56]. Concerns arise as to tumour formation
and immune reactions to allogenic sources, and there are
obvious ethical considerations. The use of stem cells is a
promising treatment in the armamentarium of the physician
or surgeon, but further research is needed to decide on the
optimal strategy in humans.
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